Morgan Stanley analyst Terence Flynn raised the firm’s price target on United Therapeutics (UTHR) to $435 from $328 and keeps an Equal Weight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target lowered to $461 from $463 at BofA
- BTIG biotech analyst holds an analyst/industry conference call
- Buy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent Litigation
- Hold Rating for United Therapeutics’ Tyvaso Amid Mixed Trial Results and Real-World Applicability Concerns
- United Therapeutics price target raised to $580 from $560 at UBS